How does Pramlintide (Symlin) work?
Synthetic amylin analog with three proline substitutions to prevent the aggregation that limits native amylin's drug suitability. Slows gastric emptying and reduces post-meal glucagon. In plain terms, Pramlintide (Symlin) is a mealtime injection that curbs appetite and steadies blood sugar in diabetics. A synthetic analog of amylin (the satiety hormone co-secreted with insulin), FDA-approved in 2005 as a mealtime adjunct in type 1 and type 2 diabetes, and the clinical predecessor to Cagrilintide. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- T1D or T2D patients struggling with post-meal glucose spikes
- Mealtime-insulin users wanting better satiety
- Educational reference for amylin pathway
References
- Pramlintide as an adjunct to insulin therapy in T1D, review — Edelman SV et al., Diabetes Technol Ther, 2008
- Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets — Hollander P et al., Diabetes, Obesity & Metabolism, 2003
- Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes — Pullman J et al., Vascular Health and Risk Management, 2006
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Pramlintide (Symlin)
Last updated 2026-06-06.